Livdelzi (Seladelpar) for PBC

Overview
Livdelzi is approved by the U.S. Food and Drug Administration (FDA) for treating primary biliary cholangitis (PBC) in adults. It is prescribed in combination with ursodeoxycholic acid (UDCA) — also known as ursodiol — for people who do not respond adequately to UDCA alone or as a monotherapy (stand-alone therapy) for those who cannot tolerate UDCA. Livdelzi is also known by its drug name, seladelpar.

Livdelzi is a peroxisome proliferator-activated receptor (PPAR)-delta agonist. It is believed to work by reducing alkaline phosphatase (ALP) levels. Alkaline phosphatase is an enzyme (protein) found in several tissues throughout the body, including the liver, bones, kidneys, and bile ducts. ALP levels are often elevated in PBC, and lowering them can help to manage the condition.

How do I take it?
Prescribing information states that Livdelzi is taken orally as a capsule once daily, with or without food. It is essential to follow the exact dosing schedule prescribed by your health care provider.

Side effects
Common side effects of Livdelzi include headache, abdominal pain, nausea, abdominal distension (bloating), and dizziness.

Rare but serious side effects may include fractures, liver test abnormalities, and biliary obstruction (blockage in the bile ducts). Monitoring and precautions should be taken as advised by a health care provider.

For more information about this treatment, visit:
Livdelzi (Seladelpar) Capsules, for Oral Use — U.S. Food and Drug Administration

Livdelzi — Drugs.com